Patents by Inventor Haoxiong QIN

Haoxiong QIN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • A COMPOUND AS A THYROID HORMONE BETA RECEPTOR AGONIST AND USE THEREOF
    Publication number: 20240025875
    Abstract: A compound serving as a thyroid hormone ? receptor agonist and uses of the compound, also provided is a pharmaceutical composition comprising the compound. The compound or the pharmaceutical composition is applicable in preparing a medicament for preventing, treating, or alleviating thyroid hormone ? receptor agonist-modulated diseases, and specifically applicable in preparing a medicament for treating nonalcoholic fatty liver disease.
    Type: Application
    Filed: September 16, 2021
    Publication date: January 25, 2024
    Applicant: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Zheng GU, Jianhao LI, Jianchao DENG, Yongxiang LI, Haoxiong QIN, Daoqian CHEN, Xiaomin ZHENG, Jianghong YU, Huantian ZHAO
  • METHOD FOR PREPARING GLUCOPYRANOSYL DERIVATIVES AND INTERMEDIATES THEREOF
    Publication number: 20230250121
    Abstract: A method for preparing glucopyranosyl derivatives as sodium dependent glucose cotransporter (SGLT) inhibitors, an intermediate thereof, and a method for preparing the intermediate.
    Type: Application
    Filed: July 7, 2021
    Publication date: August 10, 2023
    Applicant: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Zheng GU, Tong QU, Wuyong WU, Weiming HUANG, Daoqian CHEN, Zongyuan ZHANG, Haoxiong QIN, Zheng LI, Weihui YUAN, Shijie NIU, Fei PENG, Tianyun WU
  • ISOQUINOLINONE COMPOUND FOR INHIBITING SSAO/VAP-1, AND USE THEREOF
    Publication number: 20220315536
    Abstract: An isoquinolinone compound acts as an inhibitor of semicarbazide-sensitive oxidase (SSAO) and/or vascular adhesion protein-1 (VAP-1), and the use thereof, and further relates to a pharmaceutical composition containing the compound. The compound or the pharmaceutical composition can be used to prepare a drug for preventing, treating or ameliorating inflammation and/or inflammation-related diseases, diabetes and/or diabetes-related diseases in patients, and especially can be used to prepare a drug for preventing, treating or ameliorating non-alcoholic fatty liver diseases in patients.
    Type: Application
    Filed: May 20, 2020
    Publication date: October 6, 2022
    Applicant: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Zheng GU, Jianhao LI, Weihua WANG, Haoxiong QIN, Xinshan DENG
  • Amine compound for inhibiting SSAO/VAP-1 and use thereof
    Patent number: 11396495
    Abstract: An amine compound serving as a semicarbazide-sensitive amine oxidase (SSAO) and/or vascular adhesion protein-1 (VAP-1) inhibitor, a pharmaceutical composition, and an application thereof in medicines that can be used for treating inflammation and/or inflammation related diseases, diabetes and/or a disease related diabetes, psychiatric disorder, ischemic disease, vascular disease, fibrosis, or tissue transplant rejection.
    Type: Grant
    Filed: December 28, 2018
    Date of Patent: July 26, 2022
    Assignee: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Zheng Gu, Jianhao Li, Zheng Li, Weihua Wang, Haoxiong Qin, Xuli Wang, Jianyu Liu, Yingjun Zhang
  • AMINE COMPOUND FOR INHIBITING SSAO / VAP-1 AND USE THEREOF
    Publication number: 20200377461
    Abstract: An amine compound serving as a semicarbazide-sensitive amine oxidase (SSAO) and/or vascular adhesion protein-1 (VAP-1) inhibitor, a pharmaceutical composition, and an application thereof in medicines that can be used for treating inflammation and/or inflammation related diseases, diabetes and/or a disease related diabetes, psychiatric disorder, ischemic disease, vascular disease, fibrosis, or tissue transplant rejection.
    Type: Application
    Filed: December 28, 2018
    Publication date: December 3, 2020
    Applicant: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Zheng GU, Jianhao LI, Zheng LI, Weihua WANG, Haoxiong QIN, Xuli WANG, Jianyu LIU, Yingjun ZHANG